Studies have demonstrated that the down-regulation of TLR4 and NF-κB expression mitigates the organism’s inflammatory response [34], showing therapeutic efficacy in a murine model of inflammatory bowel disease through the inhibition of the TLR4/NF-κB signaling pathway [28, 35]. The gene discussed is TLR4; the disease is inflammatory bowel disease.